Puravankara was locked in lower circuit of 5% at Rs 401.40 after the company reported consolidated net loss of Rs 17.06 crore in Q2 FY25 as against net loss of Rs 11.22 crore posted in Q2 FY24.
Posts in category Business Standard
FirstCry shares fall 4%: IPO lock-in period ends, GST issue weighs (11-11-2024)
The fall in the stock price follows the end of the lock-in period for 20 million shares from the company’s initial public offering, launched in August this year
Aarti Ind, Auro Pharma, Trent stocks see short build-up; trading guide here (11-11-2024)
F&O data shows, on Friday Aarti Industries, Aurobindo Pharma and Trent saw a dip in share price alongside rise in open interest; thus implying short build-up at these counters.
Biocon soars after USFDA classifies Bengaluru unit as VAI (11-11-2024)
Biocon jumped 5.93% to Rs 340.30 after the U.S. Food and Drug Administration (FDA) has classified Biocon Biologics’ facilities at Biocon Park in Bengaluru, as ‘voluntary action indicated’ (VAI).
Puravankara shares locked in 5% lower circuit after net loss extends in Q2 (11-11-2024)
Shares of Puravankara were locked in a 5 per cent lower circuit at Rs 401.40 per share after the company reported a continuing net loss in its second quarter earnings for the financial year 2024-25
PFC shares gain 9% after reporting Q2 results; declares Rs 3.5 dividend (11-11-2024)
The company declared a second interim dividend of Rs 3.5 per share and fixed the record date as November 25, 2024
GE Vernova hits the roof after Q2 PAT soars to Rs 145 cr (11-11-2024)
GE Vernova T&D India hit an upper circuit of 5% at Rs 1774.80 after the company’s standalone net profit surged 289.08% to Rs 144.62 crore on 58.76% jump in revenue from operations to Rs 1,107.77 crore in Q2 FY25 over Q2 FY24.
China wrestles back top spot from India in MSCI Emerging Market IMI index (11-11-2024)
The change in the pecking order comes amid a sharp rally in China equities, while India has seen record foreign outflows coupled with earnings disappointment
Advanced Enzyme Technologies slips 12% on disappointing Q2 results (11-11-2024)
The specialty biotech company’s Ebitda declined 17 per cent annually to Rs 42 crore, while margins contracted 346 bps to 29 per cent during the quarter
KIMS Hospitals’ gains as Q2 PAT climbs 9% YoY; ARPOB at Rs 38,263 (11-11-2024)
Krishna Institute of Medical Sciences (KIMS) rallied 4.22% to Rs 594.25 after the company reported 9.23% increase in consolidated net profit to Rs 72.2 crore on 14.9% rise in revenue from operations to Rs 363.3 crore in Q2 FY25 over Q2 FY24.